GENOR BIOPHARMA HOLDINGS LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.21 HKD | -3.20% |
|
+3.42% | +1.68% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Genor Biopharma Holdings Ltd, formerly JHBP CY Holdings Ltd, is China-based company mainly engaged in the research and development of biopharmaceutical products. The Company focuses on the development and commercialization of oncology and autoimmune drugs. The Company's main drugs include lerociclib (GB491), coprelotamab (GB221), geptanolimab (GB226), GB492, GB242 and GB223. The Company mainly conducts its businesses in the China market.
Calendar
2024-08-27
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +1.68% | 81.25M | |
| -2.63% | 102B | |
| +1.62% | 96.29B | |
| +1.46% | 22.18B | |
| -16.67% | 21.2B | |
| -8.58% | 18.31B | |
| -38.74% | 17.38B | |
| -13.21% | 16.36B | |
| +5.41% | 13.97B | |
| +33.57% | 12.17B |
- Stock Market
- Equities
- 6998 Stock
- News Genor Biopharma Holdings Limited
- China's Drug Regulator Accepts Genor Biopharma's New Breast Cancer Drug Application; Shares Up 7%
